IL1B and systemic lupus erythematosus: SLE patients were more frequently given DEX (32% vs 14%, P = 0.05), cyclophosphamide (21% vs 3%, P = 0.01) and MMF (32% vs 2%, P < 0.001); only children with underlying sJIA received IL-1 antagonists.